Ascendis reports 9.05 cm/year height velocity at week 52 for TransCon hGH in Turner syndrome Phase 2 trial

Reuters03-17 20:33
Ascendis reports 9.05 cm/year height velocity at week 52 for TransCon hGH in Turner syndrome Phase 2 trial

Ascendis reported Week 52 topline results from the Phase 2 New InsiGHTS randomized, open-label trial comparing once-weekly TransCon hGH (lonapegsomatropin) with daily somatropin in prepubertal children with Turner syndrome. The study randomized 49 children aged 1 to 10 years, with dosing individualized based on IGF-1. At Week 52, least-squares mean annualized height velocity was 9.05 cm/year with TransCon hGH versus 9.04 cm/year with daily somatropin. Mean dose at Week 52 was 0.22 mg/kg/week for TransCon hGH and 0.29 mg/kg/week for daily somatropin. Safety follow-up extended to 143 weeks, and the company reported no occurrences of slipped capital femoral epiphysis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603170830PRIMZONEFULLFEED9673450) on March 17, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment